Etanercepet, rituximab, abatacept, tocilizumab, sarilumab (DrugBank: Rituximab, Abatacept, Tocilizumab, Sarilumab)
18 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
2 | 筋萎縮性側索硬化症 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
40 | 高安動脈炎 | 0 |
41 | 巨細胞性動脈炎 | 0 |
42 | 結節性多発動脈炎 | 0 |
43 | 顕微鏡的多発血管炎 | 0 |
46 | 悪性関節リウマチ | 1 |
50 | 皮膚筋炎/多発性筋炎 | 0 |
51 | 全身性強皮症 | 0 |
53 | シェーグレン症候群 | 0 |
54 | 成人スチル病 | 0 |
55 | 再発性多発軟骨炎 | 0 |
56 | ベーチェット病 | 0 |
86 | 肺動脈性肺高血圧症 | 0 |
107 | 若年性特発性関節炎[全身型若年性特発性関節炎(~2018.3)] | 0 |
266 | 家族性地中海熱 | 0 |
271 | 強直性脊椎炎 | 0 |
331 | 特発性多中心性キャッスルマン病 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2019-001754-25-NL (EUCTR) | 25/11/2019 | 25/11/2019 | Using adalimumab serum concentration to choose a subsequent biological treatment in rheumatoid arthritis patients failing adalimumab treatment | Using adalimumab serum concentration to choose a subsequent biological treatment in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): an open label randomized superiority trail - ADalimumab Dose Optimization in Rheumatoid Arthritis-switch (ADDORA-switch) | rheumatoid arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Enbrel, Benepali, Erelzi Product Name: Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab INN or Proposed INN: ETANERCEPT INN or Proposed INN: RITUXIMAB INN or Proposed INN: ABATACEPT INN or Proposed INN: Tocilizumab Other descriptive name: TOCILIZUMAB INN or Proposed INN: SARILUMAB | Reade | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 84 | Phase 4 | Netherlands |